文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

莫美替尼对比达那唑治疗既往接受JAK抑制剂治疗的症状性贫血骨髓纤维化患者(MOMENTUM):一项国际、双盲、随机3期研究的更新分析

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study.
PubMed 文献 · Lancet Haematol · 2023-07-27

MOMENTUM研究在24周时达到所有关键终点,显示莫美替尼对比达那唑在骨髓纤维化患者中改善症状、脾脏和贫血。本更新分析报告截至48周时24周应答的持续时间及莫美替尼的新应答。共195例患者随机(莫美替尼130例,达那唑65例),中位随访48.4周。莫美替尼在48周内持续显示症状、脾脏和贫血获益,无新安全性信号。

要点

  • 莫美替尼组48周内TSS应答率45%(30/67),达那唑交叉组50%(15/30)。
  • 开放标签期间至48周任意时间TSS应答:莫美替尼组61%(46/75),达那唑交叉组59%(19/32)。
  • 莫美替尼治疗患者最常见非血液学治疗中出现的不良事件为腹泻26%(45/171)和乏力16%(28/16)。

核心结论

  • 莫美替尼与持久的症状、脾脏和贫血获益相关,24周后出现迟发应答,且至48周安全性良好。
  • 这些结果突显莫美替尼在骨髓纤维化患者中的潜在获益,尤其是贫血患者。

研究设计与样本

  • MOMENTUM为国际、双盲、随机3期研究,在21个国家107个中心进行。
  • 纳入≥18岁原发、真性红细胞增多症后或原发性血小板增多症后骨髓纤维化患者,既往接受批准的JAK抑制剂治疗≥90天(伴血液学并发症时≥28天),ECOG体能状态≤2。
  • 患者按2:1随机分配至莫美替尼组(200 mg口服每日一次)或达那唑组(300 mg口服每日两次)至24周,分层因素为TSS(<22 vs ≥22)、脾脏大小(<12 cm vs ≥12 cm)、输血负担(0单位 vs 1-4单位 vs ≥5单位)和研究中心。
  • 24周后,两组中仍留在研究的患者均接受开放标签莫美替尼。
  • 2020年4月24日至2021年12月3日共随机195例患者(莫美替尼组130例[67%],达那唑组65例[33%])。

主要发现

  • 48周时可评估TSS的患者中,继续治疗的莫美替尼组67例中30例(45%)和交叉的达那唑组30例中15例(50%)为应答者。
  • 开放标签期间至48周任意时间TSS应答者:继续治疗的莫美替尼组75例可评估患者中46例(61%),交叉的达那唑组32例中19例(59%),包括大多数24周应答者及24周后的新应答者。
  • 长期随访未出现新的安全性信号。
  • 截至数据截止,莫美替尼治疗患者整个研究期间最常见的非血液学治疗中出现的不良事件为腹泻(45/171,26%)和乏力(28/171,16%);最常见的3-4级治疗中出现的不良事件为血小板减少(33/171,19%)和贫血(19/171,11%)。
  • 171例中79例(46%)报告严重治疗中出现的不良事件,30例(18%)报告致死性治疗中出现的不良事件;两例致死性治疗中出现的不良事件被认为可能与莫美替尼相关(轮状病毒性肠炎和金黄色葡萄球菌肺炎)。

关键数值与推荐

  • 主要终点为24周时骨髓纤维化症状评估表TSS应答率(已报告)。
  • 预设次要终点为24周TSS和输血非依赖应答的持续时间、安全性和生存,在48周数据截止(2022年5月17日)后事后总结。
  • 48周时TSS、输血非依赖和脾脏应答为事后定义,在所有进入开放标签期并提供足够数据的可评估患者中评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 48周时TSS、输血非依赖和脾脏应答为事后定义。
  • 48周数据截止后的事后总结。
  • 本更新分析的时间点为事后定义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The MOMENTUM study met all key endpoints at week 24, demonstrating symptom, spleen, and anaemia benefits with momelotinib versus danazol in patients with myelofibrosis. In this updated analysis, we report duration of week 24 responses and new responses with momelotinib through week 48. METHODS: MOMENTUM is an international, double-blind, randomised, phase 3 study done at 107 sites across 21 countries. Patients were 18 years or older with primary, post-polycythaemia vera, or post-essential thrombocythaemia myelofibrosis, previously treated with an approved Janus kinase (JAK) inhibitor for 90 days or more (≥28 days with haematological complications), and had an Eastern Cooperative Oncology Group performance status of 2 or less. Patients were randomly assigned (2:1) to either the momelotinib group (200 mg orally once per day) or danazol group (300 mg orally twice per day) through week 24 via non-deterministic biased coin minimisation and an interactive response system. Stratification factors were Total Symptom Score (TSS; <22 vs ≥22), spleen size (<12 cm vs ≥12 cm), transfusion burden (0 units vs 1-4 units vs ≥5 units), and study site. After week 24, all patients initially randomly assigned to either group who remained on the study received open-label momelotinib. The primary endpoint, which has already been reported, was Myelofibrosis Symptom Assessment Form TSS response rate at week 24. Predefined secondary endpoints were duration of week 24 TSS and transfusion independence responses, safety, and survival, which are summarised post hoc at the week 48 data cutoff (May 17, 2022). TSS, transfusion independence, and splenic responses at week 48 were defined post hoc and assessed in all evaluable patients who entered the open-label period and provided sufficient data. The timing of this updated analysis was defined post hoc after all patients had the opportunity to complete their week 48 assessments, as most patients entered an extended access study (NCT03441113) after week 48. This study is registered with ClinicalTrials.gov, number NCT04173494, and is now complete. FINDINGS: Between April 24, 2020, and Dec 3, 2021, a total of 195 patients were randomised (130 [67%] in the momelotinib group and 65 [33%] in the danazol group). 93 (72%) of 130 patients in the momelotinib group and 41 (63%) of 65 in the danazol group entered the momelotinib open-label extension period. Median follow-up was 48·4 weeks (IQR 40·6-55·7). Among TSS-evaluable patients at week 48, 30 (45%) of 67 patients in the momelotinib group who continued treatment and 15 (50%) of 30 in the danazol group who crossed over were responders. TSS responders at any time during the open-label period by week 48 were 46 (61%) of 75 evaluable patients in the momelotinib group who continued and 19 (59%) of 32 in the danazol group who crossed over, including most week 24 responders plus new responders after week 24. No new safety signals emerged with long-term follow-up. The most common non-haematological treatment-emergent adverse events in momelotinib-treated patients over the entire study period as of the data cutoff were diarrhoea (45 [26%] of 171) and asthenia (28 [16%]); the most common grades 3-4 treatment-emergent adverse events were thrombocytopenia (33 [19%]) and anaemia (19 [11%]). Serious treatment-emergent adverse events were reported in 79 (46%) of 171 patients, and fatal treatment-emergent adverse events were reported in 30 (18%); two fatal treatment-emergent adverse events were considered possibly related to momelotinib (rotaviral enteritis and Staphylococcus pneumonia). INTERPRETATION: Momelotinib was associated with durable symptom, spleen, and anaemia benefits, late responses after week 24, and favourable safety through week 48. These results highlight the potential benefits of treatment with momelotinib in patients with myelofibrosis, particularly those with anaemia. FUNDING: Sierra Oncology, a GSK company.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Gerds AT, Verstovsek S, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study. Lancet Haematol. 2023. PMID: 37517413. doi:10.1016/S2352-3026(23)00174-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。